Dr. Reddy’s Laboratories has achieved a significant regulatory win with the European Commission approving AVT03, its biosimilar for osteoporosis treatment. This authorization extends across all EU nations, plus Iceland, Liechtenstein, and Norway. Developed and manufactured by Alvotech, AVT03 will be marketed by Dr. Reddy’s in Europe and the US, offering a new option for bone health management.
Biosimilar push: Dr Reddy’s gets EU nod for denosumab copy; Prolia, Xgeva rivals set for rollout
You May Also Like
Posted in
All
Sushi Casino – Die Welt der Online Spielautomaten und Tischspiele
Posted by
Samreen Aslam